Penumbra reported third quarter 2026 revenue of $410.1 million, representing a 15.6% increase compared to the third quarter of 2025. Net income for the quarter was $42.3 million, down from $45.9 million in the prior year period. Due to the pending acquisition by Boston Scientific Corporation, the company did not provide full-year 2026 financial guidance.
Revenue reached $410.1 million in the third quarter of 2026, up 15.6% year-over-year.
Global thrombectomy revenue grew 18.1% to $279.2 million for the quarter ended September 30, 2026.
Net income for the third quarter of 2026 was $42.3 million, yielding diluted net income per share of $1.07.
Operating expenses totaled $229.6 million, including $7.1 million in acquisition-related expenses tied to the pending Boston Scientific transaction.
Penumbra reported second-quarter 2026 revenue of $390.0 million, up 14.9% from a year earlier, but net income fell to $34.8 million from $45.3 million and diluted earnings per share dropped to $0.88 from $1.15. The company will not provide full-year 2026 guidance or hold a earnings call because of its pending acquisition by Boston Scientific Corporation, leaving shareholders without a current outlook.
Q2 2026 revenue was $390.0 million, up 14.9%; thrombectomy rose 12.5% to $259.0 million and embolization and access rose 20.0% to $131.1 million.
Q2 2026 net income was $34.8 million versus $45.3 million a year earlier; the provision for income taxes was $11.4 million compared with $40 thousand.
SG&A included $6.9 million of acquisition-related expenses tied to the pending acquisition by Boston Scientific Corporation, and no full-year 2026 financial guidance will be provided.
Penumbra reported first quarter 2026 revenue of $374.8 million, up 15.6% from a year earlier, but net income fell to $32.6 million from $39.2 million and diluted earnings per share fell to $0.82 from $1.00. The company will not provide full-year 2026 guidance or hold an earnings call because of its pending acquisition by Boston Scientific.
Revenue of $374.8 million, up 15.6%; thrombectomy up 12.1% to $253.9 million and embolization and access up 23.8% to $120.8 million
Net income of $32.6 million versus $39.2 million in Q1 2025; diluted EPS of $0.82 versus $1.00
$9.4 million of acquisition-related expenses included in SG&A, tied to the pending Boston Scientific acquisition
No full-year 2026 financial guidance and no conference call, due to the pending Boston Scientific acquisition
Penumbra reported fourth quarter 2025 revenue of $385.4 million, up 22.1%, and net income of $47.3 million, compared with $33.7 million a year earlier. Full-year 2025 revenue rose 17.5% to $1,403.7 million and net income reached $177.7 million, versus $14.0 million in 2024. The company will not provide 2026 financial guidance or hold a conference call because of its proposed acquisition by Boston Scientific.
Q4 2025 diluted EPS was $1.20, compared with $0.86 in Q4 2024.
Full-year 2025 income from operations was $189.2 million, compared with $9.3 million in 2024.
No financial guidance for full-year 2026 because of the proposed acquisition by Boston Scientific Corporation (NYSE: BSX).
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.